A dihydroartemisinin nano drug and preparation method thereof
By adding sodium bicarbonate solution and glycerol-n-butanol composite solvent during the preparation of dihydroartemisinin, a nanoemulsion was prepared, which solved the problems of low loading efficiency and poor stability of dihydroartemisinin in polyethylene glycol, and improved particle size uniformity and stability, thereby increasing bioavailability.
Patent Information
- Application Number
- CN202411288104.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-14
AI Technical Summary
Existing technologies are insufficient to effectively improve the solubility and stability of dihydroartemisinin, resulting in low loading efficiency, uneven particle size, and susceptibility to demulsification and decomposition in polyethylene glycol, thus affecting bioavailability.
A nano-intermediate was formed by mixing sodium bicarbonate solution with polyethylene glycol 600 and loading glycerol and n-butanol as a composite solvent using a supercritical carbon dioxide extractor. The pH of the emulsion was adjusted to form a nano-intermediate. The nano-emulsion was then prepared by combining an oil phase and an aqueous phase matrix, which improved the loading efficiency and stability.
This study achieved efficient loading of dihydroartemisinin in polyethylene glycol, resulting in uniform particle size, good stability, and the ability to maintain emulsion stability under high temperature, high humidity, and light exposure, thereby improving bioavailability.
Smart Images

Figure CN118806749B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug preparation, and in particular to a dihydroartemisinin nano drug and a preparation method thereof. Background Art
[0002] Dihydroartemisinin, a derivative of artemisinin, is its main active metabolite. It has a strong and rapid killing effect on the erythrocytic stage of Plasmodium and can quickly control clinical attacks and symptoms. With continuous research, it is found that dihydroartemisinin has anti-inflammatory, immunosuppressive, anti-liver fibrosis and anti-tumor effects in addition to its antimalarial effect. For example, a research team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, published an article entitled RedoxDyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticlesto Potentiate Ferroptotic Therapy of Pancreatic Cancer in Small Methods. The team demonstrated that the combination of dihydroartemisinin (DHA) and the inhibitor RSL-3 can increase the sensitivity of PDAC tumor cells to ferroptosis; DHA-coupled and RSL-3-loaded nanoparticles PDBA@RSL-3 NPs combined with programmed death ligand 1 (PD-L1) blockade therapy enhances the immunotherapy effect of tumors.
[0003] Nanotechnology is a comprehensive technical system that studies and industrializes the preparation of materials at the nanoscale, and uses nanoscale materials for cross-research and industrialization. The main contents of nanotechnology research are nanoparticles, nanostructures, nanomaterials and nanodevices. Nanomedicine, in the presence of surfactants and water and other additives, directly crushes the drug into a nanosuspension, which is suitable for oral administration, injection and other routes to improve absorption or targeting. By selecting additives, particles with different surface properties can be obtained. The advantages of nanomedicine are: first, it improves the oral absorption of poorly soluble drugs. Nanoparticles can improve dissolution and solubility, increase adhesion, form metastable crystals or amorphous forms, and eliminate the supersaturation phenomenon caused by particle size differences; second, it has targeted and localized drug release. Nanoparticles have the characteristics of long circulation, invisibility and three-dimensional stability in the body, which are all conducive to drug targeting; third, it can be used as a special carrier of biomacromolecules. Improving the mucosal adhesion properties of nanoparticles obviously helps to improve effectiveness and prolong the duration of action.
[0004] Therefore, preparing the poorly soluble dihydroartemisinin into nanomedicine is beneficial to improving its solubility and thus improving its absorption and utilization rate. Summary of the invention
[0005] The purpose of the present invention is to provide a method for preparing the above-mentioned dihydroartemisinin nanomedicine. In the process of preparing the dihydroartemisinin nanomedicine, the dihydroartemisinin transfer loading efficiency is high, the dihydroartemisinin has excellent stability, is not easily degraded by external interference, and improves the bioavailability of the drug.
[0006] The present invention aims to provide a dihydroartemisinin nano drug, specifically a dihydroartemisinin nano emulsion.
[0007] The purpose of the present invention is achieved through the following technical solutions:
[0008] A method for preparing a dihydroartemisinin nano drug is characterized by comprising the steps of preparing an intermediate containing dihydroartemisinin, preparing an emulsion matrix, and mixing the intermediate and the emulsion matrix to prepare an emulsion, wherein the intermediate is prepared by mixing polyethylene glycol 600, dihydroartemisinin and a sodium bicarbonate solution to prepare a mixed solution, placing the mixed solution in a carbon dioxide supercritical extraction instrument, adding a composite solvent composed of glycerol and n-butanol, and introducing carbon dioxide for loading treatment to prepare the intermediate.
[0009] Furthermore, the mass percentage concentration of the sodium bicarbonate solution in the mixed solution is 5%, the mass ratio of polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution is 100:15~18:5~8, and the sodium bicarbonate solution is prepared by taking 95mL of purified water, adding 5g of sodium bicarbonate, and stirring to dissolve.
[0010] Furthermore, during the load treatment process, CO 2 The flow rate is 10~15kg / h, the pressure is 15~20Mpa, and the temperature is 35℃. After running for 1~2h, the pressure is increased to 25~30Mpa, the temperature is increased to 45~50℃ and maintained for 30~60min. After the end, the product is collected and placed at room temperature to obtain the intermediate product.
[0011] Furthermore, the mass ratio of the mixed solution to the composite solvent is 100:30-40, and the mass ratio of glycerol to n-butanol in the composite solvent is 3:0.8-1.
[0012] Using polyethylene glycol to load nanoparticles can improve the biocompatibility and stability of nanoparticles. However, during the loading process, it was found that the loading efficiency of dihydroartemisinin in polyethylene glycol was poor. It was difficult to transfer dihydroartemisinin to polyethylene glycol, and it was difficult for polyethylene glycol molecules to achieve uniform encapsulation of dihydroartemisinin. In addition, the nano intermediates prepared by loading had a large particle size and poor size uniformity, which affected the absorption and utilization of the drug. Demulsification was prone to occur when encapsulating the emulsion matrix. If the particle size was too small, agglomeration was prone to occur. In addition, dihydroartemisinin had poor stability due to the presence of unstable groups (internal peroxide bonds) and diastereoisomerization centers. When placed for a long time under high temperature, high humidity and strong light, dihydroartemisinin would decompose.
[0013] In the present invention, dihydroartemisinin, polyethylene glycol 600 and sodium bicarbonate are mixed into a solution, and loaded in a supercritical extractor. Glycerol and n-butanol are added during the loading process, which plays the role of an entrainer, and the regulating effect of sodium bicarbonate therein further promotes the encapsulation of bicarbonate and dihydroartemisinin by polyethylene glycol 600, thereby improving the loading efficiency of dihydroartemisinin. On the other hand, during the loading process, due to the synergistic effect of glycerol, n-butanol and sodium bicarbonate, the prepared nano intermediate has a smaller particle size and a uniform size distribution, and at the same time, the aggregation of dihydroartemisinin is suppressed, and it has good dispersibility. In addition, the addition of sodium bicarbonate regulates the pH of the final emulsion to be maintained at about 5.5 for a long time, improves the stability of dihydroartemisinin, and inhibits the degradation of dihydroartemisinin. On the other hand, the bicarbonate loaded in the system slowly decomposes and releases carbon dioxide during the long-term process. Under the cooperation of the emulsion matrix, dihydroartemisinin is effectively isolated from being affected by oxygen and light in the air, and the stability of dihydroartemisinin is further guaranteed.
[0014] Furthermore, the preparation of the emulsion matrix is as follows: liquid paraffin, stearyl alcohol, white vaseline, palm oil, and hydrogenated vegetable oil are mixed to form an oil phase matrix, glycerin, sodium lauryl sulfate, propylene glycol, ethyl hydroxybenzoate, and purified water are mixed to form an aqueous phase matrix, and the oil phase matrix is added to the aqueous phase matrix and stirred to obtain the emulsion matrix.
[0015] Furthermore, in parts by weight, the oil phase matrix comprises 8 to 10 parts of paraffin, 3 to 7 parts of octadecyl alcohol, 6 to 8 parts of white vaseline, 5 parts of palm oil, and 5 to 7 parts of hydrogenated vegetable oil; the aqueous phase matrix comprises 15 to 18 parts of glycerol, 1 to 2 parts of sodium lauryl sulfate, 10 to 12 parts of propylene glycol, 0.5 to 1 part of ethylparaben, and 70 to 80 parts of purified water.
[0016] Furthermore, the oil phase matrix is added to the aqueous phase matrix by keeping the aqueous phase matrix at 75-80° C., adding the oil phase matrix at the same temperature to the aqueous phase matrix under stirring at 60-70 rpm, continuing to stir for 10-15 minutes after the addition, and then cooling in an ice bath to obtain an emulsion matrix.
[0017] Furthermore, the preparation of the emulsion is to keep the emulsion matrix at 35-40°C, add the intermediate product while stirring at a speed of 25-30 rpm, continue stirring for 20-30 minutes after the addition is completed, and cool to room temperature to obtain the emulsion, and the mass ratio of the emulsion matrix to the intermediate product is 100:15-20.
[0018] In the process of using the emulsion matrix to wrap the nanostructured intermediate, demulsification is prone to occur, resulting in the inability of the emulsion matrix to form a complete wrapping of the intermediate, and the inability to form a nanoemulsion, so that the effective component dihydroartemisinin is easily decomposed, and the bioavailability of dihydroartemisinin is reduced. In the present invention, since the prepared intermediate itself has a small particle size and bicarbonate ions are simultaneously loaded inside, the pH of the emulsion is adjusted, and the demulsification of the intermediate is effectively suppressed, thereby forming a uniform nanoemulsion, effectively suppressing the decomposition of dihydroartemisinin caused by external environmental factors, and improving the bioavailability of dihydroartemisinin in the emulsion.
[0019] Most specifically, a dihydroartemisinin nano drug and a preparation method thereof, characterized in that it comprises the following steps:
[0020] Step 1: Preparation of intermediates
[0021] (1) Polyethylene glycol 600 is heated to 35-40°C, and dihydroartemisinin is added under stirring at 60-70 rpm. After the addition is completed, stirring is continued for 10-20 minutes. Under the same stirring conditions, a sodium bicarbonate solution with a mass concentration of 5% is added, and stirring is continued for 30-40 minutes to form a mixed solution. The mass ratio of the polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution is 100:15-18:5-8;
[0022] (2) Add the mixed solution into a supercritical carbon dioxide extractor, add a neutral solvent consisting of glycerol and n-butanol, and set the CO 2 The flow rate is 10~15kg / h, the pressure is 15~20Mpa, the temperature is 35~45℃, the operation time is 1~2h, then the pressure is increased to 25~30Mpa, the temperature is increased to 45~50℃, and it is maintained for 30~60min. After the end, the product is collected and cooled to room temperature to obtain the intermediate product;
[0023] Step (ii) Preparation of emulsion matrix
[0024] (1) According to weight, take 8-10 parts of liquid paraffin, 3-7 parts of octadecyl alcohol, 6-8 parts of white vaseline, 5 parts of palm oil, and 5-7 parts of hydrogenated vegetable oil, mix them, heat them to 75-80°C until they are melted, and obtain an oil phase matrix; separately take 15-18 parts of glycerin, 1-2 parts of sodium lauryl sulfate, 10-12 parts of propylene glycol, 0.5-1 part of ethylparaben, and 70-80 parts of purified water, heat them to 75-80°C, and stir them until they become a clear liquid, and obtain an aqueous phase matrix;
[0025] (2) Keep the water phase matrix at 75-80°C, add the oil phase matrix at the same temperature at 60-70 rm, continue stirring for 10-15 min after the addition is complete, and quickly cool to 35-40°C in an ice bath to obtain an emulsion matrix;
[0026] Step (iii) Preparation of emulsion
[0027] The emulsion matrix kept at 35-40° C. is added to the intermediate under stirring at 25-30 rpm. After the addition is completed, stirring is continued for 20-30 minutes, and then naturally cooled to room temperature to obtain an emulsion. The mass ratio of the emulsion matrix to the intermediate is 100:15-20.
[0028] A dihydroartemisinin nanoemulsion, characterized in that: a mixed solution of dihydroartemisinin, sodium bicarbonate and polyethylene glycol 600 is prepared, and a loading treatment is performed in a carbon dioxide supercritical extraction instrument with glycerol and n-butanol as a composite solvent to form an intermediate product, specifically CO 2 The flow rate is 10~15kg / h, the pressure is 15~20Mpa, and the temperature is 35℃. After running for 1~2h, the pressure is increased to 25~30Mpa, the temperature is increased to 45~50℃ and maintained for 30~60min. After the end, the product is collected and cooled to room temperature to obtain an intermediate product, which is added to the emulsion matrix to form a nanoemulsion.
[0029] Furthermore, the mass ratio of the mixed solution to the composite solvent is 100:30-40, and the mass ratio of glycerol to n-butanol in the composite solvent is 3:0.8-1.
[0030] Furthermore, the mass percentage concentration of the sodium bicarbonate solution in the mixed solution is 5%, the mass ratio of polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution is 100:15~18:5~8, and the sodium bicarbonate solution is prepared by taking 95mL of purified water, adding 5g of sodium bicarbonate, and stirring to dissolve.
[0031] Furthermore, the preparation of the emulsion matrix is as follows: liquid paraffin, stearyl alcohol, white vaseline, palm oil, and hydrogenated vegetable oil are mixed to form an oil phase matrix, glycerin, sodium lauryl sulfate, propylene glycol, ethyl hydroxybenzoate, and purified water are mixed to form an aqueous phase matrix, and the oil phase matrix is added to the aqueous phase matrix and stirred to obtain the emulsion matrix.
[0032] Furthermore, in parts by weight, the oil phase matrix comprises 8 to 10 parts of paraffin, 3 to 7 parts of octadecyl alcohol, 6 to 8 parts of white vaseline, 5 parts of palm oil, and 5 to 7 parts of hydrogenated vegetable oil; the aqueous phase matrix comprises 15 to 18 parts of glycerol, 1 to 2 parts of sodium lauryl sulfate, 10 to 12 parts of propylene glycol, 0.5 to 1 part of ethylparaben, and 70 to 80 parts of purified water.
[0033] Furthermore, the oil phase matrix is added to the aqueous phase matrix by keeping the aqueous phase matrix at 75-80° C., adding the oil phase matrix at the same temperature to the aqueous phase matrix under stirring at 60-70 rpm, continuing to stir for 10-15 minutes after the addition, and then cooling in an ice bath to obtain an emulsion matrix.
[0034] The present invention has the following technical effects:
[0035] In the present invention, when dihydroartemisinin is loaded, sodium bicarbonate is added, a carbon dioxide supercritical extraction instrument is used, glycerol and n-butanol are used as a composite solvent, the transfer rate of dihydroartemisinin in polyethylene glycol reaches 94.37%, the loaded nano intermediate product has a small particle size, and the size is evenly distributed at about 50 nm, which effectively solves the technical problem of easy demulsification, and the prepared emulsion is uniform. Dihydroartemisinin has excellent stability in the system, is not easy to decompose under long-term high temperature, high humidity and light conditions, has excellent emulsion stability, does not have the problems of stratification and sedimentation, and has excellent bioavailability. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 : Scanning electron microscope image of the intermediate prepared by the present invention. DETAILED DESCRIPTION
[0037] The present invention is described in detail below through examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Those skilled in the art can make some non-essential improvements and adjustments to the present invention based on the above-mentioned contents of the present invention.
[0038] Example 1
[0039] A dihydroartemisinin nano drug and a preparation method thereof, comprising the following steps:
[0040] Step 1: Preparation of intermediates
[0041] (1) Polyethylene glycol 600 was heated to 28°C, and dihydroartemisinin was added under stirring at 65 rpm. After the addition was completed, stirring was continued for 15 minutes. Under the same stirring conditions, a sodium bicarbonate solution with a mass concentration of 5% was added, and stirring was continued for 35 minutes to form a mixed solution. The mass ratio of the polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution was 100:16:6;
[0042] (2) Add the mixed solution into a supercritical carbon dioxide extractor, add a neutral solvent consisting of glycerol and n-butanol, and set the CO 2 The flow rate is 12 kg / h, the pressure is 18 Mpa, the temperature is 40°C, the operation time is 1.5 h, then the pressure is increased to 28 Mpa, the temperature is increased to 48°C, and it is maintained for 40 min. After the end, the product is collected and cooled to room temperature to obtain the intermediate product;
[0043] Step (ii) Preparation of emulsion matrix
[0044] (1) According to weight, 9 parts of liquid paraffin, 5 parts of octadecyl alcohol, 7 parts of white vaseline, 5 parts of palm oil, and 6 parts of hydrogenated vegetable oil are mixed and heated to 80°C until they are molten to obtain an oil phase matrix; 15-18 parts of glycerin, 1.5 parts of sodium lauryl sulfate, 11 parts of propylene glycol, 0.8 parts of ethylparaben, and 75 parts of purified water are heated to 80°C and stirred to form a clear liquid to obtain an aqueous phase matrix;
[0045] (2) The water phase matrix was kept at 80°C, and the oil phase matrix at the same temperature was added at 65 rm. After the addition was completed, stirring was continued for 12 min, and then the mixture was rapidly cooled to 38°C in an ice bath to obtain an emulsion matrix;
[0046] Step (iii) Preparation of emulsion
[0047] The emulsion matrix kept at 38° C. was added to the intermediate under stirring at 28 rpm. After the addition was completed, stirring was continued for 25 minutes, and then naturally cooled to room temperature to obtain an emulsion. The mass ratio of the emulsion matrix to the intermediate was 100:18.
[0048] The scanning electron microscope image of the intermediate product prepared in Example 1 is as follows Figure 1 As shown, it can be seen that the particle size distribution uniformity of the dihydroartemisinin intermediate prepared by the present invention is excellent, the particle size is basically distributed at about 50nm, the dispersion is good, and no agglomeration occurs.
[0049] Comparative Example 1
[0050] Compared with Example 1, low-concentration NaOH solution was used instead of sodium bicarbonate solution in Comparative Example 1 to ensure that the final emulsion pH was about 5.5. The remaining steps were the same as in Example 1.
[0051] The intermediate product prepared in this scheme has a wide particle size distribution, ranging from 100 to 170 nm, with a main distribution of 130 to 160 nm.
[0052] Comparative Example 2
[0053] Compared with Example 1, in Comparative Example 2, in the loading treatment step, an equal amount of propylene glycol is used to replace the n-butanol in the composite solvent to form a new composite solvent with glycerol, and the remaining steps are the same as those in Example 1.
[0054] The intermediate product prepared in this scheme has a wide particle size distribution, ranging from 140 to 210 nm, with 140 to 170 nm being the main distribution.
[0055] Blank control:
[0056] In the process of preparing the intermediate, no sodium bicarbonate solution was added when preparing the mixed solution, and during loading, only glycerol was used as the solvent. The remaining steps were completely consistent with Example 1.
[0057] The particle size distribution and loading efficiency of the intermediates prepared in the blank control, Example 1, Comparative Example 1 and Comparative Example 2, wherein the loading efficiency of dihydroartemisinin is calculated by the transfer rate of dihydroartemisinin to polyethylene glycol during the preparation process, and the test method is as follows:
[0058] The intermediate prepared in Example 1 was washed with ethanol, the supernatant was collected, and the content of dihydroartemisinin in the intermediate was determined by UC-vis absorption spectroscopy. Specifically, the supernatant was incubated in a 0.2% NaOH solution at 50°C for 30 minutes to convert dihydroartemisinin into an ultraviolet absorption compound, and the characteristic absorption spectrum at 290m was detected. The calculation formula is as follows:
[0059] Transfer rate = (load content of dihydroartemisinin in polyethylene glycol ÷ total amount of added dihydroartemisinin) * 100%. The results are shown in Table 1.
[0060] Table 1:
[0061]
[0062] It can be seen that the particle size of the intermediate prepared in the blank control group is relatively large, and the transfer loading of dihydroartemisinin in polyethylene glycol 600 is relatively low, and the intermediate affects the bioavailability of dihydroartemisinin. The particle size distribution of the dihydroartemisinin intermediate prepared in Example 1 is uniform, the average particle size is 49.27nm, and the transfer rate of dihydroartemisinin to polyethylene glycol is as high as 94.37%, while the particle sizes of the intermediates prepared in Comparative Examples 1 and 2 are relatively large, 147.34nm and 180.57nm, respectively, and the transfer rates of dihydroartemisinin also decrease to varying degrees, 62.73% and 79.68%, respectively.
[0063] Emulsion properties stability test:
[0064] At room temperature, 10 g of each of the emulsions prepared in Example 1, Comparative Example 1 and Comparative Example 2 were taken and placed in 5 mL centrifuge tubes, respectively, and centrifuged at 2000, 4000, 6000, 8000 and 10000 rpm for 30 min. The samples were taken out to observe whether they were stratified or agglomerated. The test results are shown in Table 2.
[0065] Table 2:
[0066]
[0067] It can be seen that the blank control group has a large particle size and the pH of the prepared emulsion is low. At a low pH, it is easier to break the emulsion and stratify, and the nanoemulsion cannot be formed. In the emulsion prepared in Example 1, under the action of high-speed centrifugation, the emulsion has excellent stability and does not have stratification, agglomeration, etc. In Comparative Examples 1 and 2, due to the large particle size of the intermediate product in the preparation, demulsification also occurred during the high-speed centrifugation process, resulting in obvious oil-water stratification in the emulsion.
[0068] Example 2
[0069] A dihydroartemisinin nano drug and a preparation method thereof, comprising the following steps:
[0070] Step 1: Preparation of intermediates
[0071] (1) Polyethylene glycol 600 was heated to 35°C, and dihydroartemisinin was added under stirring at 60 rpm. After the addition was completed, stirring was continued for 20 minutes. Under the same stirring conditions, a sodium bicarbonate solution with a mass concentration of 5% was added, and stirring was continued for 30 minutes to form a mixed solution. The mass ratio of the polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution was 100:15:5;
[0072] (2) Add the mixed solution into a supercritical carbon dioxide extractor, add a neutral solvent consisting of glycerol and n-butanol, and set the CO 2 The flow rate is 10kg / h, the pressure is 15Mpa, the temperature is 35℃, the operation time is 2h, then the pressure is increased to 30Mpa, the temperature is increased to 45℃, and it is maintained for 60min. After the end, the product is collected and cooled to room temperature to obtain the intermediate product;
[0073] Step (ii) Preparation of emulsion matrix
[0074] (1) According to weight, take 8 parts of liquid paraffin, 3 parts of octadecyl alcohol, 6 parts of white vaseline, 5 parts of palm oil, and 5 parts of hydrogenated vegetable oil, mix them, and heat them to 75°C until they are molten to obtain an oil phase matrix; separately take 15 parts of glycerin, 1 part of sodium lauryl sulfate, 10 parts of propylene glycol, 0.5 parts of ethylparaben, and 70 parts of purified water, heat them to 75°C, and stir them until they become a clear liquid to obtain an aqueous phase matrix;
[0075] (2) Keep the water phase matrix at 75°C, add the oil phase matrix at the same temperature at 70 rm, continue stirring for 15 min after the addition is complete, and quickly cool to 35°C in an ice bath to obtain an emulsion matrix;
[0076] Step (iii) Preparation of emulsion
[0077] The emulsion matrix kept at 35° C. was added to the intermediate under stirring at 25 rpm. After the addition was completed, stirring was continued for 30 minutes, and then naturally cooled to room temperature to obtain an emulsion. The mass ratio of the emulsion matrix to the intermediate was 100:15.
[0078] In the intermediate prepared in this example, the transfer rate of dihydroartemisinin was 93.92%, and the average particle size of the intermediate was 51.18 nm.
[0079] Example 3
[0080] A dihydroartemisinin nano drug and a preparation method thereof, comprising the following steps:
[0081] Step 1: Preparation of intermediates
[0082] (1) Polyethylene glycol 600 was heated to 40°C, and dihydroartemisinin was added under stirring at 70 rpm. After the addition was completed, stirring was continued for 10 minutes. Under the same stirring conditions, a sodium bicarbonate solution with a mass concentration of 5% was added, and stirring was continued for 40 minutes to form a mixed solution. The mass ratio of the polyethylene glycol 600, dihydroartemisinin and sodium bicarbonate solution was 100:18:8;
[0083] (2) Add the mixed solution into a supercritical carbon dioxide extractor, add a neutral solvent consisting of glycerol and n-butanol, and set the CO 2 The flow rate is 15kg / h, the pressure is 20Mpa, the temperature is 45℃, the operation time is 1h, then the pressure is increased to 25Mpa, the temperature is increased to 50℃, and it is maintained for 30min. After the end, the product is collected and cooled to room temperature to obtain the intermediate product;
[0084] Step (ii) Preparation of emulsion matrix
[0085] (1) According to weight, take 10 parts of liquid paraffin, 7 parts of octadecyl alcohol, 8 parts of white vaseline, 5 parts of palm oil, and 7 parts of hydrogenated vegetable oil, mix them, and heat them to 80°C until they are molten to obtain an oil phase matrix; separately take 18 parts of glycerin, 2 parts of sodium lauryl sulfate, 12 parts of propylene glycol, 1 part of ethylparaben, and 80 parts of purified water, heat them to 80°C, and stir them until they become a clear liquid to obtain an aqueous phase matrix;
[0086] (2) Keep the water phase matrix at 80°C, add the oil phase matrix at the same temperature at 60 rm, continue stirring for 10 min after the addition is complete, and quickly cool to 40°C in an ice bath to obtain an emulsion matrix;
[0087] Step (iii) Preparation of emulsion
[0088] The emulsion matrix kept at 40° C. was added to the intermediate under stirring at 25 rpm. After the addition was completed, stirring was continued for 20 minutes, and then naturally cooled to room temperature to obtain an emulsion. The mass ratio of the emulsion matrix to the intermediate was 100:20.
[0089] In the intermediate prepared in this example, the transfer rate of dihydroartemisinin was 93.87%, and the average particle size of the intermediate was 50.42 nm.
[0090] Initially, the apparent properties of Examples 1-3 and the comparative examples were basically the same. According to the relevant provisions of the 2010 edition of the Chinese Pharmacopoeia on stability research, the test environment conditions of the stability test were as follows: high temperature (60°C), high humidity (relative humidity of 92.5%), and light treatment (4500Lux). After being placed in the above single environment for 24 months, the properties of the emulsion and the content of dihydroartemisinin were tested, and the test results are shown in Table 3.
[0091] Table 3:
[0092]
[0093] As can be seen from the above table, the emulsions prepared in each embodiment of the present invention have excellent stability. After being placed under high temperature and high humidity conditions for 24 months, the properties are stable, no emulsion stratification occurs, and the content of dihydroartemisinin in the emulsion is stable and no decomposition occurs; in Comparative Example 1, due to the fact that no sodium bicarbonate was added when the intermediate was loaded and prepared, the emulsion was placed under a high temperature environment, and stratification occurred, and solid matter precipitation and agglomeration problems obviously occurred in the emulsion, and the content of dihydroartemisinin also decreased significantly under high humidity and illumination environments. In Comparative Example 2, glycerol + propylene glycol was used as a composite solvent when preparing the intermediate. Under high humidity and illumination environments, the emulsion did not stratify, but when placed at high temperature, the emulsion also had a small amount of solid matter precipitation, agglomeration and sedimentation problems, and the content of dihydroartemisinin effective components decreased significantly.
Claims
1. A method for preparing a dihydroartemisinin nano drug, characterized in that: The invention comprises the preparation of an intermediate containing dihydroartemisinin, the preparation of an emulsion matrix and the preparation of an emulsion by mixing the emulsion matrix and the intermediate in a mass ratio of 100:15-20, wherein the preparation of the intermediate comprises the following steps: mixing polyethylene glycol 600, dihydroartemisinin and a sodium bicarbonate solution having a mass percentage concentration of 5% in a mass ratio of 100:15-18:5-8 to prepare a mixed solution, placing the mixed solution in a carbon dioxide supercritical extraction instrument, adding a composite solvent composed of glycerol and n-butanol in a mass ratio of 3:0.8-1, and introducing carbon dioxide for loading treatment to prepare the intermediate, wherein the sodium bicarbonate solution is 95 mL of purified water is added with 5 g of sodium bicarbonate, and the mixture is stirred and dissolved to obtain an emulsion matrix, wherein the mass ratio of the mixed solution to the composite solvent is 100:30-40; the emulsion matrix is prepared by mixing 8-10 parts of liquid paraffin, 3-7 parts of octadecyl alcohol, 6-8 parts of white vaseline, 5 parts of palm oil, and 5-7 parts of hydrogenated vegetable oil in parts by weight to obtain an oil phase matrix, and mixing 15-18 parts of glycerin, 1-2 parts of sodium lauryl sulfate, 10-12 parts of propylene glycol, 0.5-1 part of ethyl hydroxybenzoate and 70-80 parts of purified water to obtain an aqueous phase matrix, and the oil phase matrix is added to the aqueous phase matrix and stirred to obtain an emulsion matrix.
2. The method for preparing a dihydroartemisinin nano drug according to claim 1, characterized in that: During the load treatment process, the CO2 flow rate is 10~15kg / h, the pressure is 15~20Mpa, and the temperature is 35°C. After running for 1~2h, the pressure is increased to 25~30Mpa, the temperature is increased to 45~50°C and maintained for 30~60min. After the end, the product is collected and placed at room temperature to obtain an intermediate product.
3. The method for preparing a dihydroartemisinin nano drug according to claim 2, characterized in that: The oil phase matrix is added to the water phase matrix by keeping the water phase matrix at 75-80° C., adding the oil phase matrix at the same temperature to the water phase matrix under stirring at 60-70 rpm, continuing stirring for 10-15 minutes after the addition, and then cooling in an ice bath to obtain an emulsion matrix.
4. The method for preparing a dihydroartemisinin nano drug according to claim 3, characterized in that: The preparation of the emulsion comprises the following steps: keeping the emulsion matrix at 35-40° C., adding the intermediate product while stirring at a speed of 25-30 rpm, continuing stirring for 20-30 minutes after the addition is completed, and cooling to room temperature to obtain the emulsion.
